Developing next-generation vaccines against respiratory pathogens
The Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) is divided into two entities (Research and Development).
NIVI Development enables the translational efforts of NIVI Research Center by providing industry-level expertise in vaccine development and conducting clinical studies for new vaccine candidates.
This site is the home of NIVI Development.
About us
Bridging research, translational sciences, and development
NIVI Development will catalyse progress towards achieving the NIVI mission by enabling access to cutting-edge technologies and data-driven approaches to design, test, and optimise novel vaccine candidates. NIVI Development provides capabilities and expertise – either directly, or via external strategic partnerships – to bridge exploratory research and clinical (Phase 1 & 2, including CHIM) translational development.
Harnessing airway immunity: Innovative vaccine research and development to prevent airborne epidemics
A major new vaccines research initiative launched in 2024
The Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) generates knowledge on host immunity, host-pathogen interactions, and vaccine technologies, and translates this knowledge into vaccines that provide robust, durable, and broad immunity against respiratory pathogens.
News
July 2025: Rasmus L. Krogh-Meyer, M Sc, is Director of Business Development for NIVI Development.
Rasmus L. Krogh Meyer brings with him more than 20 years of experience bridging research, innovation, and business from his former positions at Novozymes, The Danish Agency for Science and Novo Nordisk. An M. Sc in engineering specialized in biotechnology and also EBA from DTU – Technical University of Denmark, he has spent his career researching, building partnerships, negotiating license agreements, and connecting technology with real-world application.
At NIVI Development, he’ll play a key role in forming strategic collaborations, development of new partnerships and negotiating license agreements that allow researchers and developers to move forward with promising vaccine technologies.
“I’m driven by the opportunity to connect technical understanding with development potential,” Rasmus says. “The idea that something we build here could end up making a real difference in the world – that’s what motivates me.”
The aim of NIVI is to revolutionize and accelerate vaccine development in Denmark by bridging the gap between academic research and industry innovation.
NIVI Development enables the translational efforts of NIVI by providing industry-level expertise in vaccine development and conducting clinical studies (Phase 1 & 2, including CHIM) for new vaccine candidates.
“The unique setup in NIVI allows me to work at the intersection of science and strategic development,” Rasmus explains. “For me, it’s always been about bridging science and research with development strategy. I started out as a researcher, moved into technology and IP work, then into negotiations – and now I’m in a role where I connect the entire chain. That dual perspective is what I bring to the table. The idea that something we build here could end up making a real difference in the world – that’s what motivates me”, he says.
With his broad perspective – from researcher to developer – Rasmus will play a central role in shaping the platform that makes NIVI’s research translatable, scalable, and on the road for real-world implementation.
